Advertisement

Cytotechnology

, Volume 65, Issue 5, pp 791–793 | Cite as

A plea to reduce or replace fetal bovine serum in cell culture media

  • Gerhard GstraunthalerEmail author
  • Toni Lindl
  • Jan van der Valk
Letter to the Editor

To the Editor,

Fetal bovine serum (FBS) is a universal growth supplement of cell and tissue culture media. FBS is a natural cocktail of most of the factors required for cell attachment, growth, and proliferation, effective for most types of human and animal (including insect) cells. Although in use for more than 50 years, FBS has never been fully characterized. Recent proteomic and metabolomic studies revealed approx. 1,800 proteins (Anderson and Anderson 2002; Anderson et al. 2004) and more than 4,000 metabolites (Psychogios et al. 2011) present in serum. However, the use of serum in cell culture also bears a number of disadvantages. These disadvantages can either be seen from: (a) a scientific, cell biological point of view, since serum in general is an ill-defined mixture of components in culture media, with qualitative and quantitative, geographical and seasonal batch-to-batch variations, (b) from biosafety aspects, since FBS may contain adverse factors, like endotoxin,...

Keywords

Fetal Bovine Serum Tissue Culture Medium Mouth Disease Corrin Dairy Product Consumption 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Anderson NL, Anderson NG (2002) The human plasma proteome. History, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867CrossRefGoogle Scholar
  2. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A (2004) The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3:311–326CrossRefGoogle Scholar
  3. Asher DM (1999) Bovine sera used in the manufacture of biologicals: current concerns and policies of the US Food and Drug Administration regarding the transmissible spongiform encephalopathies. Dev Biol Stand 99:41–44Google Scholar
  4. Bohn B (1995) Fatal bovine serum. Nat Biotechnol 13:926–927CrossRefGoogle Scholar
  5. Brunner D, Frank J, Appl H, Schöffl H, Pfaller W, Gstraunthaler G (2010) Serum-free cell culture: the serum-free media interactive online database. ALTEX 27:53–62Google Scholar
  6. Dormont D (1999) Transmissible spongiform encephalopathy agents and animal sera. Dev Biol Stand 99:25–34Google Scholar
  7. Even MS, Sandusky CB, Barnard ND (2006) Serum-free hybridoma culture: ethical, scientific and safety considerations. Trends Biotechnol 24:105–108CrossRefGoogle Scholar
  8. Fujimoto B (2002) Fetal bovine serum—supply vs. demand? Art Sci 21:1–4Google Scholar
  9. Gstraunthaler G (2003) Alternatives to the use of fetal bovine serum: serum-free cell culture. ALTEX 20:275–281Google Scholar
  10. Gstraunthaler G, Lindl T (2013) Zell- und Gewebekultur, 7th edn. Spektrum Springer Verlag, HeidelbergCrossRefGoogle Scholar
  11. Hodgson J (1991) Checking the sources: the serum supply secret. Nat Biotechnol 9:1320–1324CrossRefGoogle Scholar
  12. Hodgson J (1993) Fetal bovine serum revisited. Nat Biotechnol 11:49–53CrossRefGoogle Scholar
  13. Hodgson J (1995) To treat or not to treat: that is the question for serum. Nat Biotechnol 13:333–343CrossRefGoogle Scholar
  14. Jochems CE, van der Valk JBF, Stafleu FR, Baumans V (2002) The use of fetal bovine serum: ethical and scientific problem? ATLA 30:219–227Google Scholar
  15. Nielsen O (1995) Changing serum’s mind-set. Nat Biotechnol 13:626CrossRefGoogle Scholar
  16. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T, Wishart DS (2011) The human serum metabolome. PLoS ONE 6:e16957CrossRefGoogle Scholar
  17. Rauch C, Feifel E, Amann E-M, Spötl HP, Schennach H, Pfaller W, Gstraunthaler G (2011) Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. ALTEX 28:305–316Google Scholar
  18. Shailer C, Corrin K (1999) Serum supply: policies and controls operating in New Zealand. Dev Biol Stand 99:71–77Google Scholar
  19. van der Valk J, Mellor D, Brands R, Fischer R, Gruber F, Gstraunthaler G, Hellebrekers L, Hyllner J, Jonker FH, Prieto P, Thalen M, Baumans V (2004) The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. Toxicol In Vitro 18:1–12CrossRefGoogle Scholar
  20. van der Valk J, Brunner D, De Smet K, Fex Svenningsen Å, Honegger P, Knudsen LE, Lindl T, Noraberg J, Price A, Scarino ML, Gstraunthaler G (2010) Optimization of chemically defined cell culture media—replacing fetal bovine serum in mammalian in vitro methods. Toxicol In Vitro 24:1053–1063CrossRefGoogle Scholar
  21. Wessmann SJ, Levings RL (1999) Benefits and risks due to animal serum used in cell culture production. Dev Biol Stand 99:3–8Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Gerhard Gstraunthaler
    • 1
    Email author
  • Toni Lindl
    • 2
  • Jan van der Valk
    • 3
  1. 1.Division of PhysiologyInnsbruck Medical UniversityInnsbruckAustria
  2. 2.Institut für Angewandte ZellkulturMunichGermany
  3. 3.3Rs—Center Utrecht Life SciencesUtrecht UniversityUtrechtThe Netherlands

Personalised recommendations